PMID- 32123839
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2573-9832 (Electronic)
IS  - 2573-9832 (Linking)
VI  - 1
IP  - 6
DP  - 2019 Jun
TI  - Molecular regulation of skeletal muscle mass and the contribution of nitric 
      oxide: A review.
PG  - 364-374
LID - 10.1096/fba.2018-00080 [doi]
AB  - A variety of internal and external factors such as exercise, nutrition, 
      inflammation, and cancer-associated cachexia affect the regulation of skeletal 
      muscle mass. Because skeletal muscle functions as a crucial regulator of whole 
      body metabolism, rather than just as a motor for locomotion, the enhancement and 
      maintenance of muscle mass and function are required to maintain health and 
      reduce the morbidity and mortality associated with diseases involving muscle 
      wasting. Recent studies in this field have made tremendous progress; therefore, 
      identification of the mechanisms that regulate skeletal muscle mass is necessary 
      for the physical and nutritional management of both athletes and patients with 
      muscle wasting disease. In this review, we present an overall picture of the 
      interactions regulating skeletal muscle mass, particularly focusing on the 
      insulin-like growth factor-I (IGF-I)/insulin-Akt-mammalian target of rapamycin 
      (mTOR) pathway, skeletal muscle inactivity, and endurance and resistance 
      exercise. We also discuss the contribution of nitric oxide (NO) to the regulation 
      of skeletal muscle mass based on the current knowledge of the novel role of NO in 
      these processes.
CI  - (c) 2019 The Authors.
FAU - Kobayashi, Jun
AU  - Kobayashi J
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Uchida, Hiroyuki
AU  - Uchida H
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Kofuji, Ayaka
AU  - Kofuji A
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Ito, Junta
AU  - Ito J
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Shimizu, Maki
AU  - Shimizu M
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Kim, Hyounju
AU  - Kim H
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Sekiguchi, Yusuke
AU  - Sekiguchi Y
AD  - Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmacy and 
      Pharmaceutical Science Josai University Saitama Japan.
FAU - Kushibe, Seiji
AU  - Kushibe S
AD  - Department of Management, Faculty of Management Josai University Saitama Japan.
LA  - eng
PT  - Journal Article
DEP - 20190411
PL  - United States
TA  - FASEB Bioadv
JT  - FASEB bioAdvances
JID - 101733210
PMC - PMC6996321
OTO - NOTNLM
OT  - fork head box O (FoxO)
OT  - mammalian target of rapamycin (mTOR)
OT  - nitric oxide synthase (NOS)
OT  - reactive oxygen species (ROS)
OT  - ubiquitin proteasome system (UPS)
COIS- No conflicts of interest, financial or otherwise, are declared by the authors.
EDAT- 2020/03/04 06:00
MHDA- 2020/03/04 06:01
PMCR- 2019/04/11
CRDT- 2020/03/04 06:00
PHST- 2018/12/21 00:00 [received]
PHST- 2019/02/12 00:00 [revised]
PHST- 2019/03/13 00:00 [accepted]
PHST- 2020/03/04 06:00 [entrez]
PHST- 2020/03/04 06:00 [pubmed]
PHST- 2020/03/04 06:01 [medline]
PHST- 2019/04/11 00:00 [pmc-release]
AID - FBA21048 [pii]
AID - 10.1096/fba.2018-00080 [doi]
PST - epublish
SO  - FASEB Bioadv. 2019 Apr 11;1(6):364-374. doi: 10.1096/fba.2018-00080. eCollection 
      2019 Jun.